Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.

Peterson AC, Harlin H, Karrison T, Vogelzang NJ, Knost JA, Kugler JW, Lester E, Vokes E, Gajewski TF, Stadler WM. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.

View in: PubMed